Condition: Endometriose

Endometriosis is defined as endometrial-like tissue outside the uterus, driving a chronic, estrogen-dependent inflammatory process with lesions, adhesions and pain. It affects roughly 10% of reproductive-aged women, is frequently invisible on ultrasound and confirmed at laparoscopy, and carries an average diagnostic delay of several years. Estrogen dependence is the basis for hormonal treatment, and inflammation the basis for the symptom pattern. Measured in: Narrative review of the disease mechanism, epidemiology and management in reproductive-aged women. This is an expert narrative review that frames the disease, not measuring a single treatment effect, so it sets context for the graded treatment claims, not standing as trial evidence itself.

In een muismodel van door oestrogeen en oxytocine gedreven baarmoederpijn verminderde zowel geïnjecteerd als intrathecaal curcumine het wroeten en verbeterde de beweging. Moleculair werk toonde aan dat curcumine de activering van gliacellen en MAPK-signalering in de dorsale wortelganglia en het ruggenmerg onderdrukte, en ontstekingsmediatoren verlaagde waaronder IL-6, TNF-alfa, IL-1bèta, CCL2 en CXCL1. Measured in: Mouse model of uterine pain induced by estrogen and oxytocin. Dit is een mechanismestudie bij muizen, vaak met geïnjecteerde doses ver boven wat een persoon absorbeert uit orale kurkuma, dus het verklaart een plausibel pad, maar toont niet aan dat curcumine endometriosepijn bij vrouwen verlicht.

In a 12-week randomized, double-blind trial, dienogest 2 mg daily reduced endometriosis-associated pelvic pain on a 100 mm visual analogue scale by a mean of 27.4 mm, against 15.1 mm with placebo, a difference of 12.3 mm in favor of dienogest (P<0.0001). Rescue analgesic use changed modestly in both arms, and dienogest was generally well tolerated. Measured in: 198 women with laparoscopically confirmed endometriosis-associated pelvic pain, randomized to dienogest 2 mg or placebo for 12 weeks. This measures pain over 12 weeks, not fertility or long-term disease control, and dienogest is a progestin that prevents pregnancy while taken, so it does not suit a woman actively trying to conceive.

Over 24 weeks, dienogest 2 mg daily and depot leuprolide acetate produced near-identical pain relief (visual analogue scale reduction 47.5 mm vs 46.0 mm), meeting the criterion for equivalence. Dienogest caused fewer hypoestrogenic effects such as hot flashes and far less bone loss: mean lumbar bone density changed by +0.25% with dienogest against -4.04% with leuprolide (P=0.0003). Measured in: 252 women with confirmed endometriosis randomized to dienogest 2 mg daily or depot leuprolide acetate for 24 weeks. This shows the two treatments are similar for pain over 24 weeks, not that either abolishes it, and the bone advantage matters most over longer use; both suppress ovulation and are unsuitable while trying to conceive.

In an open-label extension continuing dienogest 2 mg daily for up to 53 weeks, pelvic pain fell progressively during treatment (P<0.001) and bleeding irregularities settled over time. Among the subset followed after stopping, the reduction in pelvic pain persisted for at least 24 weeks off treatment. Adverse events were generally mild or moderate and led to withdrawal in 2.4%. Measured in: 168 women continuing into an open-label extension of dienogest treatment, with 34 followed during a treatment-free period. This is a single-arm open-label extension with no control group, so it shows durability under continued treatment, not proving the drug outperformed an alternative over the long run.

A Cochrane review of ten randomized trials (973 participants) found moderate-quality evidence that laparoscopic surgery to treat mild and moderate endometriosis reduces overall pain and increases live birth or ongoing pregnancy rates compared with diagnostic laparoscopy alone. Low-quality evidence from one study found excision and ablation similarly effective for pain. Measured in: Ten randomized trials of 973 women with pain or subfertility from endometriosis, mostly comparing laparoscopic ablation or excision with diagnostic laparoscopy. The evidence covers mild to moderate disease; severe disease was not well studied, pain can return over time, and the review found insufficient data on surgical harms to judge safety.

In the SAGE randomized, double-blind trial, 69 young women (aged 12 to 25) with surgically confirmed endometriosis took vitamin D3 2000 IU, fish oil 1000 mg or placebo daily for 6 months. Pain on a visual analogue scale improved in the vitamin D arm (7.0 to 5.5), but the placebo arm improved by a nearly identical amount (6.0 to 4.4), and neither supplement arm differed significantly from placebo. Measured in: 69 women aged 12 to 25 with surgically confirmed endometriosis and pelvic pain, randomized to vitamin D3, fish oil or placebo for 6 months. The trial was small and the large placebo improvement makes any true supplement effect hard to detect, so this argues against relying on these capsules as a standalone pain treatment, not settling their value for prevention.

A Cochrane review found five trials (612 women) of the combined oral contraceptive pill for endometriosis. Only three (404 women) gave analyzable data. Against placebo, the pill reduced self-reported period pain at the end of treatment, but this rested on a single small trial with wide confidence intervals, and the review graded the certainty very low. Measured in: Five randomized trials of the combined oral contraceptive pill in 612 women with endometriosis, three analyzable. The evidence is very low certainty and leans on a single small placebo-controlled trial, so the pill's wide first-line use rests more on clinical experience and its convenience than on strong trial data for endometriosis specifically.

A Cochrane review of NSAIDs for endometriosis pain could analyze only one small trial of 24 women comparing naproxen with placebo, which did not show a clear effect on pain relief (odds ratio 3.27, 95% CI 0.61 to 17.69). The certainty was very low, and the review could reach no judgment on whether NSAIDs relieve endometriosis pain. Measured in: One analyzable randomized trial of 24 women comparing naproxen with placebo for endometriosis-associated pain. Very little has been trialled here, so the quiet result reflects a gap in studies, not a measured failure; NSAIDs remain a common first step for pain and carry their own stomach and kidney effects.

Across ten trials, the six that reported pain showed acupuncture reduced endometriosis-related pain by a mean of 1.36 points on a 0 to 10 scale compared with various controls (95% CI 1.01 to 1.72, P<0.0001), and it lowered peripheral blood CA-125. Only one small pilot used a placebo needle and assessed blinding; sample sizes ranged from 8 to 36 per arm. Measured in: Ten trials of acupuncture for endometriosis-related pain, with 8 to 36 patients per arm and mostly non-placebo controls. Almost none of the trials could blind participants and all were small, so the pooled effect is an encouraging early signal for pain, not a settled result, and acupuncture is used for the wider pattern, not to clear the deposits.

In the Nurses' Health Study II (586,153 person-years, 1,199 laparoscopically confirmed cases), total fat intake was not linked to endometriosis, but women in the highest fifth of long-chain omega-3 intake were 22% less likely to be diagnosed than those in the lowest (95% CI 0.62 to 0.99, P-trend 0.03), while the highest fifth of trans-fat intake carried about a 48% higher risk than the lowest. Measured in: Prospective cohort of US women in the Nurses' Health Study II, 1,199 incident laparoscopically confirmed endometriosis cases over 12 years. What could explain it instead: Long-chain omega-3 intake tracks with overall diet quality and health-conscious behavior, so part of the lower risk may reflect the wider dietary pattern, not the fat itself.. This is a risk association over years measured by food questionnaire in women without a prior diagnosis, so it speaks to lowering the chance of developing the disease, not treating disease already present.

Among 70,556 women in the Nurses' Health Study II (1,385 confirmed cases over 14 years), those eating more than 3 servings of total dairy a day were 18% less likely to be diagnosed than those eating 2 servings (rate ratio 0.82, 95% CI 0.71 to 0.95, P-trend 0.03). Women in the highest fifth of predicted plasma 25-hydroxyvitamin D had a 24% lower risk than the lowest (rate ratio 0.76, 95% CI 0.60 to 0.97, P-trend 0.004). Measured in: Prospective cohort of 70,556 US women in the Nurses' Health Study II, 1,385 incident laparoscopically confirmed endometriosis cases. What could explain it instead: Dairy and vitamin-D intake track with overall diet, body weight and physical activity, any of which could carry part of the association independent of the nutrients themselves.. Vitamin D level was predicted from diet and lifestyle, not measured in blood, and this is a risk association in women without a prior diagnosis, so it points to prevention, not treatment.

Among 102,197 premenopausal women in the Nurses' Health Study II (996,422 person-years, 2,703 confirmed cases), the most active women (42 or more MET-hours per week) had only a slight reduction in endometriosis incidence versus the least active (fewer than 3 MET-hours), rate ratio 0.89, after adjusting for BMI, smoking, parity, infertility and menstrual factors. The earlier report of a strong inverse association was not confirmed. Measured in: Prospective cohort of 102,197 premenopausal US women in the Nurses' Health Study II, 2,703 incident laparoscopically confirmed cases. What could explain it instead: Pelvic pain can itself reduce how much a woman exercises, so undiagnosed early disease could lower activity levels, not the reverse, blunting or reversing the apparent link.. This measures the chance of developing endometriosis, not whether exercise eases pain in women who already have it, where movement is still valued for inflammation, mood and pain coping.

A Cochrane review found two Chinese randomized trials (158 women). After laparoscopic surgery, Chinese herbal medicine gave symptomatic relief comparable to the drug gestrinone (RR 1.04, 95% CI 0.91 to 1.18) with fewer reported side effects. Neither trial compared herbal medicine against a placebo. Measured in: Two Chinese randomized trials of 158 women taking Chinese herbal medicine after laparoscopic surgery for endometriosis. With only two small trials and no placebo comparison, this is a preliminary signal; in Chinese medicine the pattern decides the formula, so a mixture that suits one woman can be wrong for another, and products sold direct to the public have a documented history of adulteration.

In an observational study of women with ovarian endometriomas, 24 of those taking N-acetylcysteine cancelled scheduled laparoscopy because the cyst shrank or disappeared or pain eased, against 1 among untreated women. Eight pregnancies occurred among the N-acetylcysteine group and 6 among the untreated. The authors reported the compound was well tolerated with no side effects. Measured in: Women with ovarian endometriomas choosing N-acetylcysteine compared with untreated women awaiting surgery. What could explain it instead: Women who opted for the supplement may have had smaller or less aggressive cysts, or been more motivated to avoid surgery, either of which could explain the difference apart from the supplement.. The women were not randomly assigned, so those who chose the supplement may have differed from those who did not; the result needs a proper randomized trial before it can be relied on.